REGULUS THERAPEUTICS INC (RGLS)
US75915K3095 - Common Stock
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Regulus Therapeutics (NASDAQ:RGLS) just reported results for the first quarter ...
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels.
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Regulus Therapeutics (NASDAQ:RGLS) just reported results for the fourth quarter...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics files for $150M mixed shelf (NASDAQ:RGLS)
Regulus Therapeutics files a prospectus for a mixed shelf offering of up to $150M, as detailed in the SEC filing.
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...